These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32029537)

  • 1. PMI's heated tobacco products marketing claims of reduced risk and reduced exposure may entice youth to try and continue using these products.
    McKelvey K; Baiocchi M; Halpern-Felsher B
    Tob Control; 2020 Dec; 29(e1):e18-e24. PubMed ID: 32029537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heated tobacco products likely appeal to adolescents and young adults.
    McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IQOS: examination of Philip Morris International's claim of reduced exposure.
    St Helen G; Jacob Iii P; Nardone N; Benowitz NL
    Tob Control; 2018 Nov; 27(Suppl 1):s30-s36. PubMed ID: 30158205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IQOS labelling will mislead consumers.
    McKelvey K; Popova L; Kim M; Lempert LK; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s48-s54. PubMed ID: 30158208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Light and mild redux: heated tobacco products' reduced exposure claims are likely to be misunderstood as reduced risk claims.
    Popova L; Lempert LK; Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s87-s95. PubMed ID: 30209208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes.
    Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s9-s12. PubMed ID: 30131374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revolution or redux? Assessing IQOS through a precursor product.
    Elias J; Dutra LM; St Helen G; Ling PM
    Tob Control; 2018 Nov; 27(Suppl 1):s102-s110. PubMed ID: 30305324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
    Lempert LK; Bialous S; Glantz S
    Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PMI's IQOS and cigarette ads in Israeli media: a content analysis across regulatory periods and target population subgroups.
    Khayat A; Berg CJ; Levine H; Rodnay M; Abroms L; Romm KF; Duan Z; Bar-Zeev Y
    Tob Control; 2024 Mar; 33(e1):e54-e61. PubMed ID: 36418166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of FDA endorsement and modified risk versus exposure messaging in IQOS ads: a randomised factorial experiment among US and Israeli adults.
    Berg CJ; Duan Z; Wang Y; Thrasher JF; Bar-Zeev Y; Abroms LC; Romm KF; Khayat A; Levine H
    Tob Control; 2024 Mar; 33(e1):e69-e77. PubMed ID: 36428095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of IQOS health warnings and modified risk claims among young adult cigarette smokers and non-smokers.
    Mays D; Johnson AC; Glasser A; Mercincavage M; Strasser AA
    Tob Control; 2023 Jul; 32(4):505-508. PubMed ID: 34716283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free-Base and Total Nicotine, Reactive Oxygen Species, and Carbonyl Emissions From IQOS, a Heated Tobacco Product.
    Salman R; Talih S; El-Hage R; Haddad C; Karaoghlanian N; El-Hellani A; Saliba NA; Shihadeh A
    Nicotine Tob Res; 2019 Aug; 21(9):1285-1288. PubMed ID: 30476301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
    Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
    Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Modified Risk Tobacco Product Claims on Consumer Responses.
    Seidenberg AB; Boynton MH; Brewer NT; Lazard AJ; Sheeran P; Ribisl KM
    Nicotine Tob Res; 2024 Mar; 26(4):435-443. PubMed ID: 37791605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.
    Berg CJ; Abroms LC; Levine H; Romm KF; Khayat A; Wysota CN; Duan Z; Bar-Zeev Y
    Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IQOS marketing strategies at point-of-sales: a cross-sectional survey with retailers.
    Bar-Zeev Y; Berg CJ; Khayat A; Romm KF; Wysota CN; Abroms LC; Elbaz D; Levine H
    Tob Control; 2023 Aug; 32(e2):e198-e204. PubMed ID: 35140170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Point-of-sale marketing of heated tobacco products in Israel: cause for concern.
    Halpern-Felsher B
    Isr J Health Policy Res; 2019 May; 8(1):47. PubMed ID: 31133053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perceived relative harm and addictiveness compared with cigarettes and intentions to use modified risk tobacco products utilizing FDA-authorized marketing claims among adults in the United States.
    Tan ASL; Mercincavage M; Young WJ; Hrywna M; Delnevo CD; Strasser AA
    Drug Alcohol Depend; 2024 Aug; 261():111291. PubMed ID: 38851035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving IQOS packaging designs change perceptions of product appeal, uniqueness, quality and safety: a randomised experiment, 2018, USA.
    Lee JGL; Blanchflower TM; O'Brien KF; Averett PE; Cofie LE; Gregory KR
    Tob Control; 2019 Aug; 28(e1):e52-e55. PubMed ID: 31164489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heated tobacco product regulation under US law and the FCTC.
    Lempert LK; Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s118-s125. PubMed ID: 30291201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.